Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


May 30, 2015 11:36 AM ET

Healthcare Equipment and Supplies

Company Overview of AxoGen, Inc.

Company Overview

AxoGen, Inc. operates as a medical technology company. It offers a portfolio of nerve repair solutions for various surgical peripheral nerve repair needs. The company’s surgical nerve repair solutions include Avance Nerve Graft, a proprietary processed nerve allograft for bridging severed nerves without the comorbidities associated with a nerve autograft surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce coaptation sites while preventing soft tissue attachments. It also offe...

13631 Progress Boulevard

Suite 400

Alachua, FL 32615

United States

84 Employees

Phone:

386-462-6800

Fax:

386-462-6801

Key Executives for AxoGen, Inc.

Chief Executive Officer, President and Director
Age: 52
Total Annual Compensation: $473.3K
Chief Financial Officer
Age: 52
Total Annual Compensation: $220.9K
Senior Vice President of Business Development, General Counsel and Director
Age: 52
Total Annual Compensation: $326.8K
Senior Vice President of Sales
Age: 56
Total Annual Compensation: $384.3K
Chief Marketing Officer
Age: 48
Total Annual Compensation: $311.7K
Compensation as of Fiscal Year 2014.

AxoGen, Inc. Key Developments

AxoGen, Inc. to Report Q1, 2015 Results on May 05, 2015

AxoGen, Inc. announced that they will report Q1, 2015 results After-Market on May 05, 2015

AxoGen, Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Provides Earnings Guidance for the Year 2015

AxoGen, Inc. announced unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported revenue of $4.951 million for the first quarter ended March 31, 2015, a 58% increase compared to $3.138 million in the year-ago first quarter. Loss from operations was $2.543 million against $2.991 million a year ago. Net loss was $3.575 million or $0.16 per basic and diluted share against $4.239 million or $0.24 per basic and diluted share a year ago. Net cash used for operating activities was $2.513 million against $3.150 million a year ago. Purchase of property and equipment was $0.006 million against $0.195 million a year ago. Acquisition of intangible assets was $0.032 million against $0.008 million a year ago. For the year 2015, the company announced that given the market's increasing awareness of the company’s product portfolio and the company's plans to expand its sales footprint and sales pipeline, the company is reaffirming its 2015 full year revenue guidance of at least $24 million with annual gross margin in the mid to high 70% range.

AxoGen, Inc. - Shareholder/Analyst Call

Annual Shareholders Meeting

Similar Private Companies By Industry

Company Name Region
Althin Healthcare, Inc. United States
Vasoptic Medical Inc. United States
Socrates Health Solutions, Inc. United States
Microscopy Innovations, LLC United States
Rheologics, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AxoGen, Inc., please visit www.axogeninc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.